Podcasts about piis1470

What if the water coming out of your kitchen faucet contains chemicals specifically engineered not to break down, and the protections designed to remove them are now being rolled back? In this Fatal Conveniences episode, Darin dives into PFAS, the so-called "forever chemicals" used for decades in nonstick cookware, waterproof clothing, food packaging, firefighting foam, and countless everyday products. Their incredibly strong carbon-fluorine bonds make them extraordinarily useful, but also allow them to persist in the environment and human body for years. Darin breaks down the regulatory battle surrounding America's first legally enforceable federal drinking-water standards for several PFAS chemicals. He walks through the original 2024 EPA rule, subsequent efforts to delay or rescind portions of those protections, the court battle surrounding those changes, and why he believes the story represents something much larger than bureaucratic policy. He then traces the history back decades, discussing internal industry documents, early toxicology findings, allegations that companies withheld troubling information, and a 2018 controversy involving a federal PFAS health assessment. For Darin, it's another example of a familiar pattern: dangerous information emerging slowly while the public continues to be exposed. But this episode isn't about becoming afraid of your faucet. It's about understanding the problem so you can take action. Darin's message is simple: don't wait for corporations, regulators, or politicians to protect your health. Understand your exposure, learn what the science says, and take practical steps to protect yourself and your family. What You'll Learn What PFAS "forever chemicals" are and why they persist for so long How PFAS became embedded in everyday products and the environment Why the carbon-fluorine bond makes these chemicals so difficult to break down How PFAS can accumulate in the human body over time What the EPA's original 2024 drinking-water standards attempted to regulate Why parts of those federal PFAS protections became the subject of a regulatory and legal battle How proposed changes could delay compliance and eliminate several PFAS limits What historical internal documents revealed about early industry knowledge of PFAS toxicity Why Darin sees today's regulatory battle as part of a decades-long pattern Why understanding your own exposure and taking action matters regardless of what happens in Washington Chapters 00:00:03 – Welcome to SuperLife 00:00:34 – Sponsor: Bite 00:02:49 – Forever chemicals may already be in your blood 00:03:13 – The federal PFAS drinking-water rule and what happened next 00:03:44 – Why this episode isn't about being afraid of your faucet 00:04:07 – Stop waiting for someone else to protect your health 00:04:30 – PFAS as the ultimate Fatal Convenience 00:05:22 – The nearly unbreakable chemistry behind forever chemicals 00:05:57 – How PFAS entered everyday life 00:06:27 – Why your body struggles to eliminate these chemicals 00:06:57 – How long PFAS can remain in the body 00:07:20 – We built a civilization around a molecule with no exit plan 00:07:46 – PFAS contamination in America's drinking water 00:08:15 – The EPA's historic 2024 drinking-water standards 00:08:48 – How little PFAS it takes to trigger regulatory concern 00:09:56 – The original deadline for water utilities to comply 00:10:54 – Sponsor: Manna Vitality 00:12:49 – The PFAS rollback and what happened behind the scenes 00:13:16 – The attempt to erase standards through the courts 00:13:42 – The Safe Drinking Water Act's anti-backsliding protection 00:14:18 – The court refuses the EPA's request 00:14:49 – The 2026 proposed PFAS rule changes 00:15:33 – Why delaying compliance could affect millions of Americans 00:15:59 – The bigger story behind the PFAS rollback 00:16:35 – What internal DuPont documents revealed 00:17:12 – Toxicity findings, birth defects, and what the public was told 00:17:49 – The historic EPA penalty against DuPont 00:18:24 – The 2018 federal PFAS report controversy 00:19:03 – Why Darin believes the same pattern continues today 00:19:53 – The 60-year history of PFAS exposure 00:20:18 – What are forever chemicals actually doing to your body? 00:20:26 – Cancer risk, immune suppression, and the science coming next 00:20:36 – Can PFAS exposure happen through your shower? 00:20:44 – How to filter your home and protect your family 00:20:50 – Why Darin says we can't wait for government action 00:20:58 – Continue the full PFAS investigation on Patreon 00:21:19 – Take back control of your health Thank You to Our Sponsors Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order. Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien Find More from Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness Key Takeaway "We built an entire civilization around chemicals designed to never break down, and now they're in our water, our environment, and our bodies. But the answer isn't fear. It's awareness followed by action. We cannot control what a chemical company knew decades ago, what regulators decide tomorrow, or how quickly government moves. We can control what we bring into our homes, what we put into our bodies, how we filter our water, and how seriously we take our own health. Don't wait for someone else to save you. Learn what's happening, find the solutions available to you, and take your health back into your own hands." Bibliography/Sources: The 2024 Rule and the Rollback E&E News / POLITICO. (2026, May). EPA to roll back PFAS limits for drinking water . https://www.eenews.net/articles/epa-to-roll-back-pfas-limits-for-drinking-water/ Harvard Law School Environmental & Energy Law Program. (n.d.). EPA issued first national drinking water standard to protect against PFAS exposure . https://eelp.law.harvard.edu/tracker/epa-issued-first-national-drinking-water-standard-to-protect-against-pfas-exposure/ U.S. Environmental Protection Agency. (2024, April 10). Biden-Harris administration finalizes first-ever national drinking water standard to protect 100M people from PFAS pollution [Press release] . https://www.epa.gov/newsreleases/biden-harris-administration-finalizes-first-ever-national-drinking-water-standard U.S. Environmental Protection Agency. (2025, May 14). EPA announces it will keep maximum contaminant levels for PFOA, PFOS [Press release] . https://www.epa.gov/newsreleases/epa-announces-it-will-keep-maximum-contaminant-levels-pfoa-pfos U.S. Environmental Protection Agency. (2026, May). Proposed PFAS rescission rule . https://www.epa.gov/sdwa/proposed-pfas-rescission-rule U.S. Environmental Protection Agency. (2026, May). Proposed PFOA and PFOS compliance extension rule . https://www.epa.gov/sdwa/proposed-pfoa-and-pfos-compliance-extension-rule U.S. Environmental Protection Agency. (2026, May 11). Pre-publication Federal Register notice, PFAS rescission NPRM . https://www.epa.gov/system/files/documents/2026-05/for-prepub-web-12843-01-ow_pfas-rescission_nprm_frn_20260511_admin.pdf The Court Fight Association of State Drinking Water Administrators. (2026, January 22). DC court denies EPA's motion to vacate hazard index PFAS from drinking water rule . https://www.asdwa.org/2026/01/22/dc-court-denies-epas-motion-to-vacate-hazard-index-pfas-from-drinking-water-rule/ Fox Rothschild. (2026, March). Court denies EPA's motion to sever and stay challenges to MCLs for four index PFAS. Fox Rothschild PFAS Blog . https://pfas.foxrothschild.com/2026/03/court-denies-epas-motion-to-sever-and-stay-challenges-to-mcls-for-four-index-pfas/ National Law Review. (2026). PFAS drinking water rule case lingers in DC circuit for 18 months . https://natlawreview.com/article/pfas-drinking-water-rule-not-vacated-yet Natural Resources Defense Council. (n.d.). American Water Works Association et al. v. EPA ('Forever Chemicals' in tap water) . https://www.nrdc.org/court-battles/american-water-works-association-et-v-epa-forever-chemicals-tap-water Natural Resources Defense Council. (n.d.). What to expect in key EPA cases on PFAS and lead in drinking water . https://www.nrdc.org/media/what-expect-key-epa-cases-pfas-and-lead-drinking-water Opposition, Exposure Estimates, and Process Criticism Arizona Attorney General. (2026). Attorney General Mayes opposes EPA's rollback of PFAS limits in drinking water . https://www.azag.gov/press-release/attorney-general-mayes-opposes-epas-rollback-pfas-limits-drinking-water Earthjustice. (2025). EPA seeks to eliminate critical PFAS drinking water protections . https://earthjustice.org/press/2025/epa-seeks-to-roll-back-pfas-drinking-water-rules-keeping-millions-exposed-to-toxic-forever-chemicals-in-tap-water Environmental Protection Network. (2025, December). EPA moves to roll back PFAS drinking water protections . https://www.environmentalprotectionnetwork.org/20251209_pfas-rollback/ Environmental Protection Network. (2026, May 18). EPA's PFAS promises undermined by safeguard delays & rollbacks, along with weakened scientific capacity . https://www.environmentalprotectionnetwork.org/20260518_epa-pfas-announcement_release/ Environmental Working Group. (2026, March). New data shows 176M exposed to 'forever chemicals' as Trump EPA rolls back drinking water limits . https://www.ewg.org/news-insights/news-release/2026/03/new-data-shows-176m-exposed-forever-chemicals-trump-epa-rolls Environmental Working Group. (2026, May). Trump EPA guts landmark PFAS tap water protections, leaving millions at risk of harm . https://www.ewg.org/news-insights/news-release/2026/05/trump-epa-guts-landmark-pfas-tap-water-protections-leaving Office of Minnesota Attorney General Keith Ellison. (2026, July 21). Attorney General Ellison opposes Trump rollback of PFAS limits in drinking water . https://www.ag.state.mn.us/Office/Communications/2026/07/21_Drinking-Water.asp The New Lede. (2026, August). The EPA says they want 'PFAS out.' Their policies are allowing more of them in . https://www.thenewlede.org/2026/08/the-epa-says-they-want-pfas-out-their-policies-are-allowing-more-of-them-in/ The History of Suppression EcoWatch. (2018, May 15). Trump admin. blocked toxic chemicals study fearing 'public relations nightmare' . https://www.ecowatch.com/toxic-chemicals-study-blocked-2569008321.html Gaber, N., Bero, L., & Woodruff, T. J. (2023). The devil they knew: Chemical documents analysis of industry influence on PFAS science. Annals of Global Health, 89(1), 37 . https://annalsofglobalhealth.org/articles/10.5334/aogh.4013 Union of Concerned Scientists. (2018). Bipartisan outrage as EPA, White House try to cover up chemical health assessment . https://blog.ucs.org/michael-halpern/bipartisan-outrage-as-epa-white-house-try-to-cover-up-chemical-health-assessment/ Union of Concerned Scientists. (n.d.). How the chemical industry deployed the disinformation playbook on PFAS . https://blog.ucs.org/genna-reed/how-the-chemical-industry-deployed-the-disinformation-playbook-on-pfas/ University of California, San Francisco. (2023, May 31). Makers of PFAS 'forever chemicals' covered up the dangers . https://www.ucsf.edu/news/2023/05/425451/makers-pfas-forever-chemicals-covered-dangers Health Science IARC Monographs Working Group. (2023, November 30). Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid. The Lancet Oncology . https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00622-8/abstract International Agency for Research on Cancer. (2023, December 1). IARC Monographs evaluate the carcinogenicity of PFOA and PFOS . https://www.iarc.who.int/news-events/iarc-monographs-evaluate-the-carcinogenicity-of-perfluorooctanoic-acid-pfoa-and-perfluorooctanesulfonic-acid-pfos Ragnarsdóttir, O., Abdallah, M. A.-E., & Harrad, S. (2024). Dermal bioavailability of perfluoroalkyl substances using in vitro 3D human skin equivalent models. Environment International . https://research.birmingham.ac.uk/en/publications/dermal-bioavailability-of-perfluoroalkyl-substances-using-in-vitr/ University of Birmingham. (2024, June). New study confirms forever chemicals are absorbed through human skin . https://www.birmingham.ac.uk/news/2024/new-study-confirms-forever-chemicals-are-absorbed-through-human-skin-1 U.S. Environmental Protection Agency. (2024, April). PFAS national primary drinking water regulation — Questions and answers . https://www.epa.gov/system/files/documents/2024-04/pfas-npdwr_qa_general_4.9.24v1.pdf Home Filtration Evidence and How-to Duke University. (2020, February 5). Not all in-home drinking water filters completely remove toxic PFAS [Press release]. EurekAlert . https://www.eurekalert.org/news-releases/694230 Environmental Working Group. (2025, September). PFAS in drinking water: What you need to know . https://www.ewg.org/news-insights/news/2025/09/pfas-drinking-water-what-you-need-know Herkert, N. J., Merrill, J., Peters, C., et al. (2020). Assessing the effectiveness of point-of-use residential drinking water filters for perfluoroalkyl substances (PFASs). Environmental Science & Technology Letters, 7(3), 178–184 . https://pubs.acs.org/doi/10.1021/acs.estlett.0c00004 Tap Score. (n.d.). Quick guide to NSF certified filters for PFAS . https://mytapscore.com/blogs/tips-for-taps/quick-guide-to-certified-filters-for-pfas State Action Ballard Spahr. (2026, June). EPA rolls back PFAS regulations, states fill the gap . https://www.ballardspahr.com/insights/alerts-and-articles/2026/06/epa-rolls-back-pfas-regulations-states-fill-the-gap Bryan Cave Leighton Paisner. (n.d.). PFAS drinking water standards: State-by-state regulations . https://www.bclplaw.com/en-US/events-insights-news/pfas-drinking-water-standards-state-by-state-regulations.html

Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology. To read the publications discussed, see:  Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group:  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6   Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0

5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed treatment decision considering long-term QOL effects for intermediate-risk early breast cancer. Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00122-1/fulltext

Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas, fulfilling the requirement for a methodical, systematic, and uniform approach to the diagnosis, treatment response assessment and post-therapy surveillance of osteosarcoma and Ewing sarcoma. Click here to read the full article:  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00141-5/fulltext

In this first part of a special two-episode series of TOGA's Conversations in Lung Cancer Research podcast, A/Prof Deme Karikios, a Medical Oncologist at the Nepean Hospital in NSW, is joined by Prof Ken O'Byrne, a Consultant and Professor in Medical Oncology at the Princess Alexandra Hospital and the Queensland University of Technology, and A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide. The panel discusses the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia, including the removal of 'once in a life time' rule. This major structural shift moves oncology prescribing away from rigid, indication-specific silos and toward clinician discretion guided by a patient's individual biology and the best available clinical evidence. This episode also covers what this means for advanced and metastatic thoracic malignancies, the biological rationale behind single versus doublet immunotherapy, and the practicalities of managing these clinical decisions. Podcast Sponsor Note: This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers. Resource Links: CM816 https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 CM9LA https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/abstract CM227-https://www.nejm.org/doi/full/10.1056/NEJMoa1910231 CM227 was a clinical trial that examined ipi/nivo, nivo alone or chemotherapy in pts with NSCLC with PD-L1 expression level of 1%   (00:00) Welcome and Acknowledgement (02:00) New PBS Listing Explained (04:18) Defining Advanced and Sensitive (07:18) Dual vs Single Immunotherapy (12:27) Early Stage and Recurrence (14:26) Duration Stopping and Restarting (20:57) Other Thoracic Cancers (23:55) System Impact and Wrap Up Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltextTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide.https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltextTell us what you thought about this episodeMedical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children's Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children's Research Hospital) to discuss qualitative in oncology.Read the full Reviews:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00669-2 for The Power of Words: Evaluating the Role of Qualitative Methods in Cancer Researchand https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00670-9 for Expert Recommendations for the Conduct and Appraisal of Qualitative Research in Oncologyand the reviews in  Lancet Haematology 2026  https://doi.org/10.1016/S2352-3026(25)00321-7and eClinicalMedicine https://doi.org/10.1016/j.eclinm.2025.103736Tell us what you thought about this episodeMedical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA. Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00593-5/fulltextTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltextTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas.In these two cohort studies, the authors analyse the expression of TERT and TERT promoter mutations in meningiomas, assess their association with patient outcomes, and discuss the potential implications for patient management and the classification of these tumours.You can read the two Articles here:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00267-0/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanonchttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00422-X/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

When is Y90 the right treatment for metastatic disease? Join Drs. Tyler Sandow, Zach Berman and host Kavi Krishnasamy in the conclusion of Dosimetry University where they discuss the complexities of treating different variations of metastatic disease and review how they've approached complicated cases with Y90. --- SYNPOSIS The interventional oncologists first outline the types of metastases that they treat, including colorectal, lung, cholangiocarcinoma, breast, gastric, RCC, and melanoma. The doctors then discuss the potential for Y90 to provide palliative relief by reducing tumor-related pain. The conversation also covers key differences between treating liver-dominant and liver-only disease, along with their algorithm for patients not on systemic chemotherapy.The episode then covers advanced concepts in Y90, such as sub-ablative dosing, the possibility of creating an abscopal effect, and how radiation thresholds change depending on treatment goals. They outline their approach to partition dosimetry, using SPECT/CT to calculate tumor-to-normal ratios, and explain how they modify particle counts and microsphere activity, using flow augmentation based on tumor vascularity. Additional discussion includes the impact of mutation status, prior lines of chemotherapy, and tumor response criteria like RECIST 1.1 and mRECIST. The experts conclude with a case series that illustrates decision-making around when to consider Y90, thermal ablation, TACE, or alternative approaches—even in complex cases like sphincter of Oddi dysfunction. The session underscores the nuanced nature of advanced dosimetric techniques and the evolving landscape of interventional oncology. --- TIMESTAMPS 00:00 - Introduction 01:30 - Types of Metastases Treated with Y9002:50 - Liver-Dominant vs. Liver-Only Disease 07:20 - Sub-Ablative Dosing and the Abscopal Effect09:55 - Tips for Partition Dosimetry 15:30 - Clinical Factors in Treatment Planning23:50 - Choosing Ablation, Resection, or Y90 for mCRC30:27 - Case Series: Colorectal Metastases, Biliary Complications, and more46:00 - Final Thoughts: The Evolving Field --- RESOURCES RECIST 1.1 and mRECIST Criteria:https://pmc.ncbi.nlm.nih.gov/articles/PMC9161105/ COLLISION Trial:https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA3501 BackTable Episode on COLLISION Trial:https://www.youtube.com/watch?v=NQLKcv1BRVM FOXFIRE, SIRFLOX, FOXFIRE-Global:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30457-6/fulltext

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00239-6?dgcid=buzzsprout_icw_podcast_July_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutatedKOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstractSAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-ofKOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9 

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tloRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo#asco2025Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, and Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167Articles discussed in this podcast episode include:Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlwClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlwRelacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw#asco2025Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations. They discuss the disease burden of advanced melanoma with BRAF mutations, the key findings from the EBIN trial, and the future implications of the study findings, especially for a select sub-population of patients with advanced melanoma.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00133-0/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In de podcastserie Proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze speciale aflevering spreekt zij met dr. Paul Hengeveld over zijn proefschrift, getiteld: ‘Molecular risk stratification in chronic lymphocytic leukemia'. Paul vertelt hoe moleculaire risicostratificatie kan helpen in voorspellen van de prognose van patiënten met chronische lymfatische leukemie (CLL) en filosofeert over de toekomst van MRD (measurable residual disease) bij CLL. Paul heeft 27 maart 2024 zijn proefschrift succesvol verdedigd aan de Erasmus Universiteit bij prof. dr. Ton Langerak en co-promotoren dr. Mark-David Levin en dr. Peter Westerweel. Hij kreeg dit jaar tijdens de hematologiedagen het Jaap Steenbergen Stipendium voor het beste hematologieproefschrift van 2024.Referenties Inspiratietip: Belgische televisieserie - Met gevoel voor tumor Prognose CLL – THEMIS2 MRD CLL10 Sequentiële MRD HOVON-139 FLAIR-studie

In de podcastserie Proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze speciale aflevering spreekt zij met dr. Paul Hengeveld over zijn proefschrift, getiteld: ‘Molecular risk stratification in chronic lymphocytic leukemia'. Paul vertelt hoe moleculaire risicostratificatie kan helpen in voorspellen van de prognose van patiënten met chronische lymfatische leukemie (CLL) en filosofeert over de toekomst van MRD (measurable residual disease) bij CLL. Paul heeft 27 maart 2024 zijn proefschrift succesvol verdedigd aan de Erasmus Universiteit bij prof. dr. Ton Langerak en co-promotoren dr. Mark-David Levin en dr. Peter Westerweel. Hij kreeg dit jaar tijdens de hematologiedagen het Jaap Steenbergen Stipendium voor het beste hematologieproefschrift van 2024.Referenties Inspiratietip: Belgische televisieserie - Met gevoel voor tumor Prognose CLL – THEMIS2 MRD CLL10 Sequentiële MRD HOVON-139 FLAIR-studie

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial.This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of the trial, including the detection rates of clinically significant prostate cancer, infection risks, patient experiences, and the potential implications for clinical practice and health policy.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00100-7/fulltext?dgcid=buzzsprout_tlv_podcast_30-04-25_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In de podcastserie proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze aflevering spreekt zij met dr. Teska Schuurman over haar proefschrift, getiteld: “Tailored care in fertile women with cancer”. Teska bespreekt de aanleiding voor haar onderzoek en verschillende studies die ze deed om de behandeling van AYA's (adolescents and young adults) te kunnen personaliseren om fertiliteit te kunnen behouden indien gewenst. Teska heeft op 24 maart haar proefschrift succesvol verdedigd aan de Universiteit van Amsterdam bij dr. Christianne Lok, dr. Nienke van Trommel en prof. dr. Frederic Amant.Referenties Boek: Even ontspannen, mevrouw – Mieke Kerkhof Tamoxifen in de zwangerschap.Literatuurstudie fertiliteit sparende chirurgie voor gynaecologische tumoren. Fertiliteit sparende chirurgie voor voorstadium cervixcarcinoom (AIS). Individualiseren van follow-up na fertiliteit sparende chirurgie voor cervixcarcinoom.

In de podcastserie proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze aflevering spreekt zij met dr. Teska Schuurman over haar proefschrift, getiteld: “Tailored care in fertile women with cancer”. Teska bespreekt de aanleiding voor haar onderzoek en verschillende studies die ze deed om de behandeling van AYA's (adolescents and young adults) te kunnen personaliseren om fertiliteit te kunnen behouden indien gewenst. Teska heeft op 24 maart haar proefschrift succesvol verdedigd aan de Universiteit van Amsterdam bij dr. Christianne Lok, dr. Nienke van Trommel en prof. dr. Frederic Amant.Referenties Boek: Even ontspannen, mevrouw – Mieke Kerkhof Tamoxifen in de zwangerschap.Literatuurstudie fertiliteit sparende chirurgie voor gynaecologische tumoren. Fertiliteit sparende chirurgie voor voorstadium cervixcarcinoom (AIS). Individualiseren van follow-up na fertiliteit sparende chirurgie voor cervixcarcinoom.

Today, after a brief discussion of shows Ali and Asif have been watching lately – including ‘One Day' and ‘Adolescence' (as well as shows they bailed on… ‘Breaking Bad' and ‘The White Lotus') – they discuss ‘Apple Cider Vinegar' and Belle Gibson (7:43). They go over Belle Gibson's rise from Instagram “Wellness Warrior” to being exposed as faking having brain cancer. They then discuss the Netflix TV show based on Belle Gibson's story ‘Apple Cider Vinegar'. They discuss how the show weaves in Belle's story with the fictionalized character of Milla who is closely based on Jessica Ainscough, a prominent Australian influencer who billed herself as Wellness Warrior who did in fact have cancer. They then give their thoughts on the show including Kaityn Dever's amazing performance.    Then, based on the recent outbreaks in North America, Ali asks Asif about Measles (26:48). Asif talks about what it is and how it is one of the most contagious infectious diseases. Asif then talks about who is at risk of contracting measles including the unvaccinated, children under age 1 year and the immunocompromised. Asif goes over the symptoms and the potential fatal complications. He then goes over how it is treated. Then Ali asks Asif about the reasons for declining vaccination rates.    The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions.    Music courtesy of Wataboi and 8er41 from Pixabay   Contact us at doctorvcomedian@gmail.com   Follow us on Social media: Twitter: @doctorvcomedian Instagram:  doctorvcomedian   Show Notes: Unmasking Belle Gibson: The real story of the infamous wellness scammer: https://www.youtube.com/watch?v=fahOX8VBXCc The Cancer Scams That Foreshadowed MAHA: https://www.newyorker.com/culture/cultural-comment/the-cancer-scams-that-foreshadowed-maha The Search for Instagram's Worse Con Artist: https://www.netflix.com/ca/title/81987249 The rise and fall of the wellness warriors: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30207-9/abstract A play-by-play of how measles outbreaks can spiral out of control: https://www.cbc.ca/news/health/measles-second-opinion-march-2025-1.7476500 Ask an expert: Why are we seeing measles outbreaks across Canada and who should get vaccinated? https://www.dal.ca/news/2025/03/27/measles-outbreak-expert.html Measles: https://www.ncbi.nlm.nih.gov/books/NBK448068/ Measles vaccines: Canadian Immunization Guide: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-12-measles-vaccine.html

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In the past five years, the use of immunotherapeutic agents for advanced cancers has emerged as a promising alternative to tyrosine kinase inhibitors and chemotherapy, making it an exciting time to be practicing oncology. In this episode, Dr. Tyler Sandow interviews oncology experts about the landscape of advanced hepatocellular carcinoma (HCC) and the current state of immunotherapy treatments. He is joined by medical oncologists Dr. Jonathan Mizrah, Dr. Lingling Du, and Dr. Adam Burgoyne, as well as interventional oncologist Dr. Zachary Berman. Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion: https://www.cmeuniversity.com/course/take/125737 --- This podcast is supported by an educational grant from: AstraZeneca https://www.astrazeneca.com/our-therapy-areas/oncology.html With additional support from: Boston Scientific https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology.html --- SYNPOSIS Drs. Burgoyne and Mizrahi provide a primer on immunotherapy and explain how they communicate the principles of this treatment to their patients. Dr. Du discusses the Imbrave clinical trial and how recent studies have shown improved overall survival when immunotherapeutic agents are used, especially when multiple agents targeting various pathways are employed. When choosing between different regimens, the doctors consider factors such as the patient's underlying liver function, symptom burden, and prior treatments. Importantly, the doctors also discuss contraindications to immunotherapy, including a history of organ transplant, autoimmune disease, and poor performance status—all of which put patients at high risk for deterioration with this treatment. The treatment of patients with poor liver function remains controversial, as underlying cirrhosis may prevent the recovery of liver function. Dr. Berman outlines recent clinical trials studying the effects of transarterial chemoembolization (TACE) combined with immunotherapy. Finally, the doctors discuss the future of HCC treatment and the benefits of continued innovation in both interventional and medical oncology. --- TIMESTAMPS 00:00 - Introduction to Immunotherapy 04:32 - Notable Clinical Trials 13:39 - HCC Etiology and Immunotherapy Outcomes 18:43 - Contraindications for Immunotherapy 23:05 - Adverse Effects from Treatment 25:14 - Combination Therapy 36:22 - Considerations for Immunotherapy Dosing 40:26 - The Future of HCC Treatment --- RESOURCES Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, IMbrave150 Trial (Finn et al, 2020): https://pubmed.ncbi.nlm.nih.gov/32402160/ Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma, HIMALAYA Trial (Abou-Alfa et al, 2022): https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100070 Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial (Yau, 2022): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/abstract Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW (Galle, 2024): https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA4008 Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment (Llovet, 2022): https://pubmed.ncbi.nlm.nih.gov/35119481/ Find this episode on BackTable.com for more resources.

In this episode of SurgOnc Today®, Dr. Julie Hallet, Chair of the HPB Disease Site Work Group, and Dr. Patricio Polanco, Vice-Chair of the HPB Disease Site Work Group, are joined by Drs. Sajid Khan from Yale School of Medicine and Dr. Cecilia Ethun from UT Southwestern. They will wrap the 2024 HPB year by reviewing the top HPB surgical oncology published this year.  References/Resources: #10: AMPLIFY https://www.nature.com/articles/s41591-023-02760-3   #9: Adjuvant therapy for IPMN-derived PDAC - https://ascopubs.org/doi/abs/10.1200/JCO.23.02313   #8: HELIX https://jamanetwork.com/journals/jama/fullarticle/2822555  #7: CAMINO  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00572-7/fulltext  #5 : PANDAS/PRODIGE https://www.annalsofoncology.org/article/S0923-7534(24)03884-5/fulltext

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.Read the full Articles here:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonchttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial'.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

The  @OncoAlert Round Up Covering July 26-Aug 1, 2024   REGISTER at http://Oncoalert360.com or https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration DiscussingShield Blood test FDAApproved for #ColorectalCancer Screeninghttps://ascopost.com/news/july-2024/guardant-health-s-shield-blood-test-approved-by-the-fda-as-a-primary-screening-option-for-colorectal-cancer/INSIGHT Trial in #NSCLC https://thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00270-5/abstractCombining PSMA-PETand PROMISE in #ProstateCancer https://sciencedirect.com/science/article/pii/S1470204524003267Review in RCC #KidneyCancer @b_szabados @drfrankiejs @tompowles1 https://thelancet.com/journals/lancet/article/PIIS0140-6736(24)00917-6/abstract Immune & Gene Expressionin ER Low & Neg #BreastCancer by @vitti10 https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djae178/7724836?searchresult=1&login=false Top Advances of the year: #Immunotherapy & #EndometrialCancer @BanerjeeSusana @PelegHasson https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35417ASCOGuidelines on cannabis in Adults Cancerhttps://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35461?af=R

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00071-8?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.'Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode, we dive into the management of newly diagnosed and relapsed FLT3-positive AML with Dr. Alexander Perl.Here are the shownotes:1. Assessment of minimal residual disease in standard-risk AML https://www.nejm.org/doi/full/10.1056/nejmoa1507471 2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutationhttps://www.nejm.org/doi/full/10.1056/nejmoa1614359 3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext 4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groupshttps://ashpublications.org/blood/article/127/12/1551/35035/Benefit-of-high-dose-daunorubicin-in-AML-induction 5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.2017.72.8618?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapyhttps://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs 7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AMLhttps://www.nejm.org/doi/full/10.1056/nejmoa1902688 8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemiahttps://ascopubs.org/doi/10.1200/JCO.22.00602?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023. 10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30455-1/fulltext?dgcid=raven_jbs_etoc_email

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium's recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.Read the full Policy Review:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall survival and progression-free survival. The issue lies in the sequencing of therapies and how to make treatment durable and better tolerated for all. Third, immunotherapy is not ready for primetime in this cohort of patients, and the reasons are unclear. Not to be outdone, bladder cancer continues to make strides in patient care with a phase 1 study that may be lost in no-man land or could harbour a shift in trial design with antibody drug conjugates. Today, we discuss the following trials:Articles discussed in this episode. Subscription may be required:Keynote 641 (Pembrolizumab + enzalutamide in the metastatic castrate-resistant prostate cancer sphere)https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2819%2930688-6/fulltextPSMAfore trial (LuPSMA in taxane naive patients)https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639061MAGNITUDE Study (Niraparib and abiraterone)https://esmocongress.esmo.org/esmo/esmo2023/en-GB/presentation/639153The DAD study (sacituzumab govitecan (SG) plus enfortumab vedotin (EV)https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00563-6/fulltextFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Hosted on Acast. See acast.com/privacy for more information. Hosted on Acast. See acast.com/privacy for more information.

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

In this episode, Anthony and Bernie chat with Chris Booth, MD, and Aaron "Papa Heme" Goodman, MD, to talk about the Common Sense Oncology movement! Join the Common Sense Oncology movement at this link (it's free!): https://commonsenseoncology.org/ Lancet Oncol paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00319-4/fulltext

To start the episode, Ali and Asif discuss the controversy surrounding country singer Miranda Lambert chastising concertgoers for taking selfies (0:48). Then, after a brief digression on Dana Carvey's Joe Biden impression, Asif asks Ali about the surprise hit TV show ‘Jury Duty' (10:32). They discuss the background of the show and how it is a combination of ‘The Office' and ‘The Joe Schmo Show'. They then discuss how the show did not make much of a splash when it first debuted, but then gained buzz via TikTok. Ali and Asif then discuss the show's reception and  their thoughts on the show. They then discuss the Emmy nominations the show has received, including James Marsden for best supporting actor…for playing himself. Then the guys RE-discuss artificial sweeteners because of a new press-release issued by the WHO on the possible carcinogenic effects of aspartame (37:45). Asif explains how it was a joint press release, highlighting findings about   aspartame are released today by the International Agency for Research on Cancer (IARC) and the World Health Organization (WHO) and the Food and Agriculture Organization (FAO) Joint Expert Committee on Food Additives (JECFA). Overall, Asif explains how the IARC found “limited evidence” for carcinogenicity in humans aand classified aspartame as possibly carcinogenic to humans. He then explains that JECFA reaffirmed the acceptable daily intake of 40 mg/kg body weight (ie an adult weighing 70kg would need to consume more than 9–14 cans per day to exceed the acceptable daily intake). Asif clarifies how  the agencies' statements are "complementary" in that the two groups work differently, and have a different aim: while IARC flags a potential hazard based on even limited evidence, JECFA assesses the real-life risk.   A reminder that the pod will be taking a month off in August. Look for new episodes coming your way on Sept 8, 2023!   The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions.    Music courtesy of Wataboi and 8er41 from Pixabay   Contact us at doctorvcomedian@gmail.com   Follow us on Social media: Twitter: @doctorvcomedian Instagram: doctorvcomedian   Show notes: Miranda Lambert has a point: https://www.avclub.com/miranda-lambert-scolds-fans-at-show-backlash-1850651000 How Jury Duty Orchestrated the Trial of a Lifetime: https://www.vulture.com/article/jury-duty-interview.html How 'Jury Duty' completely faked a trial in real courtroom with a narcissistic James Marsden: https://www.usatoday.com/story/entertainment/tv/2023/04/08/jury-duty-feevee-series-fakes-civil-trial-james-marsden/11610571002/ Their Show Flew Under the Radar. TikTok Blew It Up: https://www.nytimes.com/2023/06/08/arts/television/jury-duty-freevee.html How Jury Duty became the surprise comedy breakout of the year: https://www.theguardian.com/tv-and-radio/2023/jul/17/show-jury-duty-amazon-freevee-tiktok What is aspartame and what do the new WHO rulings mean? https://www.reuters.com/business/healthcare-pharmaceuticals/what-is-aspartame-what-do-new-who-rulings-cancer-consumption-mean-2023-07-13/ Opinion: What the WHO aspartame findings mean for your diet: https://www.cnn.com/2023/07/21/opinions/aspartame-sweetener-diet-world-health-organization-branca/index.html Does Aspartame Cause Cancer or Is It Safe to Consume? The Latest Evidence About the Artificial Sweetener: https://time.com/6294701/aspartame-cancer-sweetener-studies/ Ninety-sixth meeting - Joint FAO/WHO Expert Committee on Food Additives (JECFA): https://www.who.int/publications/m/item/ninety-sixth-meeting-joint-fao-who-expert-committee-on-food-additives-(jecfa) IARC Monographs Hazard Classification: https://www.iarc.who.int/wp-content/uploads/2023/06/IARC_MONO_classification_2023_updated.png Carcinogenicity of aspartame, methyleugenol, and isoeugenol: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00341-8/fulltext Summary of findings of the evaluation of aspartame at the International Agency for Research on Cancer (IARC) Monographs Programme's 134th Meeting, and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) 96th meeting: https://www.who.int/publications/m/item/summary-of-findings-of-the-evaluation-of-aspartame-at-the-international-agency-for-research-on-cancer-(iarc)-monographs-programme-s-134th-meeting--and-the-joint-fao-who-expert-committee-on-food-additives-(jecfa)-96th-meeting

“Aspartam kommer på WHO's kræftliste.” Det var én af de mange overskrifter, man kunne læse, da det for to uger siden blev afsløret, at Verdenssundhedsorganisationen ville klassificere sødemidlet som ‘muligvis kræftfremkaldende'. Nu er WHO udkommet med deres begrundelse – men siger samtidig, at det ikke er skadeligt at indtage. Og det har – forståeligt nok – skabt både frygt og forvirring. I denne episode gennemgår vi WHO pressemeddelselse samt de forskellige instanser, IARC og JECFA, der er involveret i asapartam-udmeldingen og hvad der egentlig er op og ned på kategoriseringen af aspartam. Vi besvarer ud fra det spørgsmålet: Er der grund til bekymring for aspartam skulle være skadeligt at indtage? Hvis du vil støtte podcasten, så finder du vores sponsor Zetland lige her. Du får to måneders lytbar, reklamefri, dommedagsfri kvalitetsjournalistik for 50 kroner i alt. Det er under en tredjedel af normalprisen: zetland.dk/slutmedforbudt Ting, vi nævner i podcasten: Elsøes Instagram-opslag, der opsummerer hele sagen: https://www.instagram.com/p/CutgghKNoKh/  Pressemeddelelsen fra WHO, der både indeholder konklusionen fra IARC og JECFA: https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released Artiklen i Lancet, der indeholder IARC's begrundelse for vurderingen af aspartam: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00341-8/fulltext JECFA's begrundelse for stadig at vurdere, at aspartam er sikkert at indtage: https://www.who.int/publications/m/item/ninety-sixth-meeting-joint-fao-who-expert-committee-on-food-additives-(jecfa) IARC's database over alt, de har har vurderet til dato: https://monographs.iarc.who.int/list-of-classifications/  EFSA's kritik af de italienske aspartam-forsøg, der – som de eneste – konkluderede, at aspartam var kræftfremkaldende i mus: https://www.efsa.europa.eu/en/news/efsa-assesses-new-aspartame-study-and-reconfirms-its-safety 

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

De novo metastatic breast cancer represents 6% of all new breast cancer diagnoses. This figure has not changed at all over the past 20 years; however, systemic therapy options have evolved dramatically during this time and have significantly increased life expectancy for these patients. While surgical management of the primary tumor in the setting of metastatic disease has typically been reserved for palliative indications, surgeons are now being asked to consider resecting the primary tumor to potentially increase overall survival. In this episode, we will use a case study to examine the data that should inform our conversations and decisions when we encounter patients with metastatic breast cancer who are interested in having their primary tumor resected. Links: Khan, S.A., S. Schuetz, and O. Hosseini (2022). Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review. Ann Surg Oncol; 29: 5811-5820. https://link.springer.com/article/10.1245/s10434-022-11900-x Khan, S.A. et al (2022). Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). J Clin Oncol; 40(9): 978-987. https://ascopubs.org/doi/10.1200/JCO.21.02006?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Badwe, R. et al (2015). Locoregional treatment versus no treatment of the primary tumor in metastatic breast cancer: an open-label randomized controlled trial. Lancet Oncol; 16: 1380-1388. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00135-7/fulltext Fitzal, F. et al (2019). Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg; 269(6): 1163-1169. https://journals.lww.com/annalsofsurgery/Abstract/2019/06000/Impact_of_Breast_Surgery_in_Primary_Metastasized.24.aspx Soran, A. et al (2018). Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol; 25: 3141-3149. https://link.springer.com/article/10.1245/s10434-018-6494-6 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out other breast surgery episodes here: https://behindtheknife.org/podcast-category/breast/

De novo metastatic breast cancer represents 6% of all new breast cancer diagnoses. This figure has not changed at all over the past 20 years; however, systemic therapy options have evolved dramatically during this time and have significantly increased life expectancy for these patients. While surgical management of the primary tumor in the setting of metastatic disease has typically been reserved for palliative indications, surgeons are now being asked to consider resecting the primary tumor to potentially increase overall survival. In this episode, we will use a case study to examine the data that should inform our conversations and decisions when we encounter patients with metastatic breast cancer who are interested in having their primary tumor resected. Links: §  Khan, S.A., S. Schuetz, and O. Hosseini (2022). Primary-Site Local Therapy for Patients with De Novo Metastatic Breast Cancer: An Educational Review. Ann Surg Oncol; 29: 5811-5820. https://link.springer.com/article/10.1245/s10434-022-11900-x §  Khan, S.A. et al (2022). Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). J Clin Oncol; 40(9): 978-987. https://ascopubs.org/doi/10.1200/JCO.21.02006?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed §  Badwe, R. et al (2015). Locoregional treatment versus no treatment of the primary tumor in metastatic breast cancer: an open-label randomized controlled trial. Lancet Oncol; 16: 1380-1388. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00135-7/fulltext §  Fitzal, F. et al (2019). Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial. Ann Surg; 269(6): 1163-1169. https://journals.lww.com/annalsofsurgery/Abstract/2019/06000/Impact_of_Breast_Surgery_in_Primary_Metastasized.24.aspx §  Soran, A. et al (2018). Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol; 25: 3141-3149. https://link.springer.com/article/10.1245/s10434-018-6494-6 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our other clinical challenges episodes here: https://behindtheknife.org/podcast-series/clinical-challenges/

  Vidcast:  https://youtu.be/SfP3br735Mk   The brain is surrounded by a barrier that protects it from blood-borne toxins.  Usually a benefit, it complicates the treatment of brain tumors.  Columbia University neurosurgeons have now developed a catheter and pump combo that bypasses this blood-brain barrier and pumps cancer-killing chemo directly into a cancer's depths.  This permits the safe perfusion of the tumor with drugs at 1000-fold higher concentrations than if they were introduced intravenously or by mouth.  The semi-permanent pump is installed in the patient's abdomen and its reservoir is refillable via a skin port.   https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00599-X/fulltext   #braincancer #chemotherapy #implantablepump #glioma  

Warning!  There is magic contained in this podcast.  Real magic.  The kind of magic that allows you to understand how to manage the axilla in breast cancer patients.    The standard of care approach to management of the axilla in patients with breast cancer has evolved rapidly. While a complete axillary dissection was historically indicated following identification of any positive nodes, that is no longer the case; indeed, axillary dissections are now uncommonly performed. Join Drs. Michael Alvarado, Rita Mukhtar, and Alexa Glencer as they discuss the impact of the ACOSOG Z0011, AMAROS, and ACOSOG Z1071 trials in defining the role of sentinel lymph node dissection and radiotherapy in patients with early-stage breast cancer with limited lymph node involvement as well as the approach when neoadjuvant chemotherapy has been received. Learning Objectives: ·       Describe the study design and results of the ACOSOG Z0011 trial and its impact on the use of sentinel lymph node biopsy as an alternative to complete axillary lymph node dissection in clinically node-negative patients with T1 or T2 breast cancer ·       Describe the study design and results of the AMAROS trial and its implications for use of axillary radiation as an alternative to axillary lymph node dissection for patients with clinically node-negative T1 or T2 breast cancer ·       Understand the risk of lymphedema related to complete axillary lymph node dissection, as demonstrated by the AMAROS trial ·       Describe the study design and results of the ACOSOG Z1071 trial and how interpretation of its subgroup analysis has been applied to our approach of offering sentinel lymph node biopsy as a means of staging the axilla following neoadjuvant chemotherapy in patients with clinical node-positive disease at the time of diagnosis Journal Article Links: ACOSOG Z0011: https://jamanetwork.com/journals/jama/article-abstract/2653737 AMAROS: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70460-7/fulltext ACOSOG Z1071: https://jamanetwork.com/journals/jama/fullarticle/1748149%20 Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.